

My MISSION Support

Lean on us for assistance and support throughout treatment with **MONJUVI® (tafasitamab-cxix)**

See the following pages for more details.

What is MONJUVI?

MONJUVI (tafasitamab-cxix) is a prescription medicine given with lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who cannot receive a stem cell transplant.

It is not known if MONJUVI is safe and effective in children.

The approval of MONJUVI is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of MONJUVI.

IMPORTANT SAFETY INFORMATION

Important information I should know, including possible side effects, about MONJUVI:

MONJUVI may cause serious side effects, including infusion-related reactions, low blood cell counts, and infections.

Please see the full [Prescribing Information](#), including Patient Information, for additional Important Safety Information.

MONJUVI[®]
tafasitamab-cxix | 200mg
for injection, for intravenous use

My MISSION Support provides support—including financial assistance for people who are eligible, ongoing education, and other resources—throughout the treatment journey.

This includes:



Call Center

For personalized support from a My MISSION Support Program Specialist, call 855-421-6172, Monday to Friday, 8 AM to 8 PM ET.



Patient Financial Assistance Programs*

We can work with you to understand your insurance coverage and medication cost, and explore financial assistance options as you begin and continue treatment with MONJUVI.



Patient Support and Education

When you enroll, specially trained professionals are available to support you by:

- ▶ Providing general information about DLBCL that has returned or stopped responding to treatment
- ▶ Conducting routine phone-based check-ins
- ▶ Answering questions you may have about MONJUVI

**Enroll in My MISSION Support today by calling 855-421-6172
or visiting our website at [MyMISSIONSupport.com](https://www.MyMISSIONSupport.com).**

DLBCL=diffuse large B-cell lymphoma.

*Other terms and conditions apply. Visit www.MyMISSIONSupport.com for full eligibility criteria.

IMPORTANT SAFETY INFORMATION (cont'd)

Important information I should know, including possible side effects, about MONJUVI (cont'd):

The most common side effects of MONJUVI include feeling tired or weak, diarrhea, cough, fever, swelling of lower legs or hands, respiratory tract infection, and decreased appetite.

These are not all the possible side effects of MONJUVI. Your healthcare provider will give you medicines before each infusion to decrease your chance of infusion reactions. If you do not have any reactions, your healthcare provider may decide that you do not need these medicines with later infusions. Your healthcare provider may need to delay or completely stop treatment with MONJUVI if you have severe side effects.

Please see the full [Prescribing Information](#), including Patient Information, for additional Important Safety Information.



Connect with our Program Specialists for personalized assistance and information from compassionate professionals whose goal is to help you throughout treatment with MONJUVI.

Here's how it works:

1 **Enroll by phone or online**

To enroll in My MISSION Support, call 855-421-6172 or visit our website at [MyMISSIONSupport.com](https://www.MyMISSIONSupport.com).

2 **Speak with a program specialist**

Once enrolled, you will receive a welcome call to introduce you to the program and discuss what you may expect during your treatment journey.

3 **Check in regularly**

Following an initial welcome call, a trained professional may check in with you periodically, based on your preference, to answer certain questions and provide disease information and support as needed.

My MISSION Support professionals do not provide medical advice. Your healthcare team is the single best source of medical advice regarding your treatment. Please consult your healthcare team if you have any questions about your treatment.

IMPORTANT SAFETY INFORMATION (cont'd)

Before receiving MONJUVI, tell your healthcare provider about all your medical conditions, including if you have an active infection or have had one recently, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. You should not become pregnant or breastfeed during treatment with MONJUVI and should use an effective method of birth control (contraception) and not breastfeed during and for at least 3 months after your last dose of MONJUVI. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with MONJUVI. **Refer to the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation.**

Please see the full [Prescribing Information](#), including Patient Information, for additional Important Safety Information.



My MISSION SUPPORT

Patient
Support
Program™

Enroll in My MISSION Support today by visiting our website at
[MyMISSIONSupport.com](https://www.MyMISSIONSupport.com).

IMPORTANT SAFETY INFORMATION (cont'd)

Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to MORPHOSYS US INC. at (844) 667-1992.

Please see the full [Prescribing Information](#), including Patient Information, for additional Important Safety Information.

morphosys



MONJUVI and the MONJUVI logo are registered trademarks of MorphoSys AG.
© 2021 July 2021 RC-US-TAF-01103
Distributed and marketed by MorphoSys US Inc. and marketed by Incyte Corp.
MorphoSys is a registered trademark of MorphoSys AG.
Incyte and the Incyte logo are registered trademarks of Incyte Corp.
All other trademarks are the property of their respective owner(s).

MONJUVI[®]
tafasitamab-cxix | 200mg
for injection, for intravenous use